

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: H. William Bosch et al.
Title: NOVEL NIMESULIDE COMPOSITIONS
Appl. No.: 10/697,703
Filing Date: 10/31/2003
Examiner: Sara E. CLARK
Art Unit: 1612
Confirmation Number: 8369

AMENDMENT AND REPLY UNDER 37 CFR 1.114

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This communication is responsive to the Final Office Action dated July 9, 2009, concerning the above-referenced patent application. This paper accompanies a Request for Continued Examination (RCE) and is part of the RCE submission. By virtue of the accompanying Petition for Extension of Time and payment of the prescribed fees, this response is time filed on or before November 9, 2009.

Listing of Claims begins on page 2 of this document.

Remarks/Arguments begin on page 26 of this document.

LISTING OF CLAIMS

1. (Previously Presented) A nimesulide composition comprising:
 - (a) particles of nimesulide or a salt thereof, wherein the particles have an effective average particle size of less than 2000 nm; and
 - (b) at least one surface stabilizer adsorbed on the surface of the nimesulide particles.
2. (Previously Presented) The composition of claim 1, wherein the nimesulide is selected from the group consisting of a crystalline phase, an amorphous phase, and a semi-crystalline phase.
3. (Previously Presented) The composition of claim 1, wherein the effective average particle size of the nimesulide particles is selected from the group consisting of less than 1900 nm, less than 1800 nm, less than 1700 nm, less than 1600 nm, less than 1500 nm, less than 1400 nm, less than 1300 nm, less than 1200 nm, less than 1100 nm, less than 1000 nm, less than 900 nm, less than 800 nm, less than 700 nm, less than 600 nm, less than 500 nm, less than 400 nm, less than 300 nm, less than 250 nm, less than 200 nm, less than 100 nm, less than 75 nm, and less than 50 nm.
4. (Original) The composition of claim 1, wherein the composition is formulated for administration selected from the group consisting of oral, pulmonary, rectal, ophthalmic, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, local, buccal, nasal, and topical administration.
5. (Original) The composition of claim 1 formulated into a dosage form selected from the group consisting of liquid dispersions, oral suspensions, gels, aerosols, ointments, creams, controlled release formulations, fast melt formulations, lyophilized formulations, tablets, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations.

6. (Original) The composition of claim 1, wherein the composition further comprises one or more pharmaceutically acceptable excipients, carriers, or a combination thereof.

7. (Original) The composition of claim 1, wherein the nimesulide or a salt thereof is present in an amount selected from the group consisting of from about 99.5% to about 0.001%, from about 95% to about 0.1%, and from about 90% to about 0.5%, by weight, based on the total combined dry weight of the nimesulide or a salt thereof and at least one surface stabilizer, not including other excipients.

8. (Original) The composition of claim 1, wherein the at least one surface stabilizer is present in an amount selected from the group consisting of from about 0.5% to about 99.999% by weight, from about 5.0% to about 99.9% by weight, and from about 10% to about 99.5% by weight, based on the total combined dry weight of the nimesulide or a salt thereof and at least one surface stabilizer, not including other excipients.

9. (Original) The composition of claim 1, comprising two or more surface stabilizers.

10. (Previously Presented) The composition of claim 1, wherein the surface stabilizer is selected from the group consisting of an anionic surface stabilizer, a cationic surface stabilizer, a zwitterionic surface stabilizer, a non-ionic surface stabilizer, and an ionic surface stabilizer.

11. (Original) The composition of claim 10, wherein the at least one surface stabilizer is selected from the group consisting of cetyl pyridinium chloride, gelatin, casein, phosphatides, dextran, glycerol, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, dodecyl trimethyl ammonium bromide, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate,

carboxymethylcellulose calcium, hydroxypropyl celluloses, hypromellose, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hypromellose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde, poloxamers; poloxamines, a charged phospholipid, dioctylsulfosuccinate, dialkylesters of sodium sulfosuccinic acid, sodium lauryl sulfate, alkyl aryl polyether sulfonates, mixtures of sucrose stearate and sucrose distearate, p-isononylphenoxypoly-(glycidol), decanoyl-N-methylglucamide; n-decyl β -D-glucopyranoside; n-decyl β -D-maltopyranoside; n-dodecyl β -D-glucopyranoside; n-dodecyl β -D-maltoside; heptanoyl-N-methylglucamide; n-heptyl- β -D-glucopyranoside; n-heptyl β -D-thioglucoside; n-hexyl β -D-glucopyranoside; nonanoyl-N-methylglucamide; n-noyl β -D-glucopyranoside; octanoyl-N-methylglucamide; n-octyl- β -D-glucopyranoside; octyl β -D-thioglucopyranoside; lysozyme, PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, and random copolymers of vinyl acetate and vinyl pyrrolidone.

12. (Original) The composition of claim 10, wherein the at least one cationic surface stabilizer is selected from the group consisting of a polymer, a biopolymer, a polysaccharide, a cellulosic, an alginate, a nonpolymeric compound, and a phospholipid.

13. (Previously Presented) The composition of claim 10, wherein the surface stabilizer is selected from the group consisting of cationic lipids, polymethylmethacrylate trimethylammonium bromide, sulfonium compounds, polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate, hexadecyltrimethyl ammonium bromide, phosphonium compounds, quarternary ammonium compounds, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride, coconut trimethyl ammonium bromide, coconut methyl dihydroxyethyl ammonium chloride, coconut methyl dihydroxyethyl ammonium bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride bromide,

C₁₂₋₁₅dimethyl hydroxyethyl ammonium chloride, C₁₂₋₁₅dimethyl hydroxyethyl ammonium chloride bromide, coconut dimethyl hydroxyethyl ammonium chloride, coconut dimethyl hydroxyethyl ammonium bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride, lauryl dimethyl benzyl ammonium bromide, lauryl dimethyl (ethenoxy)₄ ammonium chloride, lauryl dimethyl (ethenoxy)₄ ammonium bromide, N-alkyl (C₁₂₋₁₈)dimethylbenzyl ammonium chloride, N-alkyl (C₁₄₋₁₈)dimethyl-benzyl ammonium chloride, N-tetradecyldimethylbenzyl ammonium chloride monohydrate, dimethyl didecyl ammonium chloride, N-alkyl and (C₁₂₋₁₄) dimethyl 1-naphthylmethyl ammonium chloride, trimethylammonium halide, alkyl-trimethylammonium salts, dialkyl-dimethylammonium salts, lauryl trimethyl ammonium chloride, ethoxylated alkyamidoalkyldialkylammonium salt, an ethoxylated trialkyl ammonium salt, dialkylbenzene dialkylammonium chloride, N-didecyldimethyl ammonium chloride, N-tetradecyldimethylbenzyl ammonium, chloride monohydrate, N-alkyl(C₁₂₋₁₄) dimethyl 1-naphthylmethyl ammonium chloride, dodecyldimethylbenzyl ammonium chloride, dialkyl benzenealkyl ammonium chloride, lauryl trimethyl ammonium chloride, alkylbenzyl methyl ammonium chloride, alkyl benzyl dimethyl ammonium bromide, C₁₂ trimethyl ammonium bromides, C₁₅ trimethyl ammonium bromides, C₁₇ trimethyl ammonium bromides, dodecylbenzyl triethyl ammonium chloride, poly-diallyldimethylammonium chloride (DADMAC), dimethyl ammonium chlorides, alkyl dimethylammonium halogenides, tricetyl methyl ammonium chloride, decyltrimethylammonium bromide, dodecyltriethylammonium bromide, tetradecyltrimethylammonium bromide, methyl trioctylammonium chloride, polyquaternium 10, tetrabutylammonium bromide, benzyl trimethylammonium bromide, choline esters, benzalkonium chloride, stearylalkonium chloride compounds, cetyl pyridinium bromide, cetyl pyridinium chloride, halide salts of quaternized polyoxyethylalkylamines, quaternized ammonium salt polymers, alkyl pyridinium salts; amines, amine salts, amine oxides, imide azolinium salts, protonated quaternary acrylamides, methylated quaternary polymers, and cationic guar.

14. (Original) The composition of claim 1, comprising as a surface stabilizer a random copolymer of vinyl acetate and vinyl pyrrolidone, hydroxypropylmethyl cellulose, or tyloxapol.

15. (Original) The composition of any of claims 10, 12, or 13, wherein the composition is bioadhesive.

16. (Original) The composition of claim 1, wherein the T_{\max} of the nimesulide, when assayed in the plasma of a mammalian subject following administration, is less than the T_{\max} for a conventional, non-nanoparticulate form of nimesulide, administered at the same dosage.

17. (Previously Presented) The composition of claim 16, wherein the T_{\max} is selected from the group consisting of not greater than 90%, not greater than 80%, not greater than 70%, not greater than 60%, not greater than 50%, not greater than 30%, not greater than 25%, not greater than 20%, not greater than 15%, and not greater than 10% of the T_{\max} , exhibited by a non-nanoparticulate formulation of nimesulide, administered at the same dosage.

18. (Original) The composition of claim 1, wherein the C_{\max} of the nimesulide, when assayed in the plasma of a mammalian subject following administration, is greater than the C_{\max} for a conventional, non-nanoparticulate form of nimesulide, administered at the same dosage.

19. (Previously Presented) The composition of claim 18, wherein the C_{\max} is selected from the group consisting of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, and at least 100% greater than the C_{\max} exhibited by a non-nanoparticulate formulation of nimesulide, administered at the same dosage.

20. (Original) The composition of claim 1, wherein the AUC of the nimesulide, when assayed in the plasma of a mammalian subject following administration, is greater than the AUC for a conventional, non-nanoparticulate form of nimesulide, administered at the same dosage.

21. (Previously Presented) The composition of claim 20, wherein the AUC is selected from the group consisting of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, and at least 100% greater than the AUC exhibited by a non-nanoparticulate formulation of nimesulide, administered at the same dosage.

22. (Previously Presented) The composition of claim 1 which does not produce a difference in the absorption levels of the nimesulide composition when administered to a patient under fed as compared to fasting conditions.

23. (Previously Presented) The composition of claim 22, wherein the difference in absorption of the nimesulide composition of the invention, when administered in the fed versus the fasted state, is selected from the group consisting of less than 100%, less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, and less than 3%.

24. (Original) The composition of claim 1, wherein administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state, when administered to a human.

25. (Original) The composition of claim 24, wherein "bioequivalency" is established by a 90% Confidence Interval of between 0.80 and 1.25 for both C_{max} and AUC, when administered to a human.

26. (Original) The composition of claim 24, wherein "bioequivalency" is established by a 90% Confidence Interval of between 0.80 and 1.25 for AUC and a 90% Confidence Interval of between 0.70 to 1.43 for C_{max} , when administered to a human.

27. (Previously Presented) The composition of claim 1, further comprising at least one additional nimesulide composition having an effective average particle size which is different than the effective average particle size of the nimesulide composition of claim 1.

28. (Previously Presented) The composition of claim 1, wherein upon administration the composition redisperses such that the nimesulide particles have an effective average particle size of less than 2000 nm.

29. (Previously Presented) The composition of claim 28, wherein upon administration the composition redisperses such that the nimesulide particles have an effective average particle size selected from the group consisting of less than 1900 nm, less than 1800 nm, less than 1700 nm, less than 1600 nm, less than 1500 nm, less than 1400 nm, less than 1300 nm, less than 1200 nm, less than 1100 nm, less than 1000 nm, less than 900 nm, less than 800 nm, less than 700 nm, less than 600 nm, less than 500 nm, less than 400 nm, less than 300 nm, less than 250 nm, less than 200 nm, less than 150 nm, less than 100 nm, less than 75 nm, and less than 50 nm.

30. (Previously Presented) The composition of claim 1, wherein the composition redisperses in a biorelevant media such that the nimesulide particles have an effective average particle size of less than 2 microns.

31. (Previously Presented) The composition of claim 30, wherein the composition redisperses in a biorelevant media such that the nimesulide particles have an effective average particle size selected from the group consisting of less than 1900 nm, less than 1800 nm, less than 1700 nm, less than 1600 nm, less than 1500 nm, less than 1400 nm, less than 1300 nm, less than 1200 nm, less than 1100 nm, less than 1000 nm, less than 900 nm, less than 800 nm, less than 700 nm, less than 600 nm, less than 500 nm, less than 400 nm, less than 300 nm, less than 250 nm, less than 200 nm, less than 150 nm, less than 100 nm, less than 75 nm, and less than 50 nm.

32. (Withdrawn) The composition of claim 1 formulated into a liquid dosage form, wherein the dosage form has a viscosity of less than 2000 mPa·s, measured at 20°C, at a shear rate of 0.1 (1/s).

33. (Withdrawn) The composition of claim 32, having a viscosity at a shear rate of 0.1 (1/s) selected from the group consisting of from about 2000 mPa·s to about 1 mPa·s, from about 1900 mPa·s to about 1 mPa·s, from about 1800 mPa·s to about 1 mPa·s, from about 1700 mPa·s to about 1 mPa·s, from about 1600 mPa·s to about 1 mPa·s, from about 1500 mPa·s to about 1 mPa·s, from about 1400 mPa·s to about 1 mPa·s, from about 1300 mPa·s to about 1 mPa·s, from about 1200 mPa·s to about 1 mPa·s, from about 1100 mPa·s to about 1 mPa·s, from about 1000 mPa·s to about 1 mPa·s, from about 900 mPa·s to about 1 mPa·s, from about 800 mPa·s to about 1 mPa·s, from about 700 mPa·s to about 1 mPa·s, from about 600 mPa·s to about 1 mPa·s, from about 500 mPa·s to about 1 mPa·s, from about 400 mPa·s to about 1 mPa·s, from about 300 mPa·s to about 1 mPa·s, from about 200 mPa·s to about 1 mPa·s, from about 175 mPa·s to about 1 mPa·s, from about 150 mPa·s to about 1 mPa·s, from about 125 mPa·s to about 1 mPa·s, from about 100 mPa·s to about 1 mPa·s, from about 75 mPa·s to about 1 mPa·s, from about 50 mPa·s to about 1 mPa·s, from about 25 mPa·s to about 1 mPa·s, from about 15 mPa·s to about 1 mPa·s, from about 10 mPa·s to about 1 mPa·s, and from about 5 mPa·s to about 1 mPa·s.

34. (Withdrawn) The composition of claim 32, wherein the viscosity of the dosage form is selected from the group consisting of less than 1/200, less than 1/100, less than 1/50, less than 1/25, and less than 1/10 of the viscosity of a liquid dosage form of conventional non-nanoparticulate nimesulide at about the same concentration per ml of nimesulide.

35. (Withdrawn) The composition of claims 32, wherein the viscosity of the dosage form is selected from the group consisting of less than 5%, less than 10%, less than 15%, less than 20%, less than 25%, less than 30%, less than 35%, less than 40%, less than 45%, less than 50%, less than 55%, less than 60%, less than 65%, less than 70%, less than 75%, less than 80%,

less than 85%, and less than 90% of the viscosity of a liquid dosage form of conventional, non-nanoparticulate nimesulide at about the same concentration per ml of nimesulide.

36. (Original) The composition of claim 1, additionally comprising one or more non-nimesulide active agents.

37. (Previously Presented) The composition of claim 36, wherein said non-nimesulide active agent is selected from the group consisting of an analgesic, an anti-inflammatory, an antipyretic, and a vasomodulator.

38. (Original) The composition of claim 36, wherein said non-nimesulide active agent is selected from the group consisting of nutraceuticals, proteins, peptides, nucleotides, amino acids, anti-obesity drugs, central nervous system stimulants, carotenoids, corticosteroids, elastase inhibitors, anti-fungals, oncology therapies, anti-emetics, analgesics, cardiovascular agents, anti-inflammatory agents, NSAIDs, non-nimesulide COX-2 inhibitors, anthelmintics, anti-arrhythmic agents, antibiotics, anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytics, sedatives, astringents, alpha-adrenergic receptor blocking agents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiac inotropic agents, contrast media, corticosteroids, cough suppressants, diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics, haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones, anti-allergic agents, stimulants and anoretics, sympathomimetics, thyroid agents, vasodilators, vasomodulators, and xanthines.

39. (Withdrawn) The composition of claim 38, wherein said nutraceutical is selected from the group consisting of lutein, folic acid, fatty acids, fruit extracts, vegetable extracts, vitamin supplements, mineral supplements, phosphatidylserine, lipoic acid, melatonin,

glucosamine/chondroitin, Aloe Vera, Guggul, glutamine, amino acids, green tea, lycopene, whole foods, food additives, herbs, phytonutrients, antioxidants, flavonoid constituents of fruits, evening primrose oil, flax seeds, fish oils, marine animal oils, and probiotics.

40. (Original) The composition of claim 36, wherein said non-nimesulide active agent is selected from the group consisting of aceclofenac, acetaminophen, acetaminosalol, acetanilide, acetylsalicylic acid, S-adenosylmethionine, alclofenac, alfentanil, allylprodine, alminoprofen, aloxiprin, alphaprodine, aluminum bis(acetylsalicylate), amfenac, aminochlorlorthenoxazin, 3-amino-4-hydroxybutyric acid, 2-amino-4-picoline, aminopropyl, aminopyrine, amixetrine, ammonium salicylate, ampiroxican, amtolmetin guacil, anileridine, antipyrine, antipyrine salicylate, antrafenine, apazone, bendazac, benorylate, benoxaprofen, benzpiperylon, benzydamine, benzylmorphine, bermoprofen, bezitramide, α -bisabolol, bromfenac, p-bromoacetanilide, 5-bromosalicylic acid acetate, bromosaligenin, buccetin, bucloxic acid, bucolome, buprenorphine, butacetin, butibufen, butophanol, calcium acetylsalicylate, carbamazepine, carbiphen, carprofen, carsalam, chlorobutanol, chlorthenoxazin, choline salicylate, cinchophen, cinmetacin, ciramadol, clidanac, clometacin, clonitazene, clonixin, clopirac, clove, codeine, codeine methyl bromide, codeine phosphate, codeine sulfate, cropropamide, crotethamide, desomorphine, dexodrol, dextromoramide, dezocine, diampromide, diclofenac sodium, difenamizole, difenpiramide, diflunisal, dihydrocodeine, dihydrocodeinone enol acetate, dihydromorphine, dihydroxyaluminum acetylsalicylate, dimenoxadol, dimepethanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, diprocetyl, dipyrone, ditazol, droxicam, emorfazone, enfenamic acid, eprizole, eptazocine, etersalate, ethebamide, ethebamazine, ethoxazene, ethylmethylthiambutene, ethylmorphine, etodolac, etofenamate, etonitazene, eugenol, felbinac, fenbuten, fenclozic acid, fendosal, fenoprofen, fentanyl, fentiazac, fepradinol, feprazone, floctafenine, flufenamic acid, flunoxaprofen, fluoresone, flupirtine, fluproquazone, flurbiprofen, fosfosal, gentisic acid, glafenine, glucametacin, glycol salicylate, guaiazulene, hydrocodone, hydromorphone, hydroxypethidine, ibufenac, ibuprofen, ibuprofen, imidazole salicylate,

indomethacin, indoprofen, isofezolac, isoladol, isomethadone, isonixin, isoxepac, isoxicam, ketobemidone, ketoprofen, ketorolac, p-lactophenetide, lefetamine, levorphanol, lofentanil, lonazolac, lomoxicam, loxoprofen, lysine acetylsalicylate, magnesium acetylsalicylate, meclofenamic acid, mefenamic acid, meperidine, meptazinol, mesalamine, metazocine, methadone hydrochloride, methotrimeprazine, metiazinic acid, metofoline, metopon, mofebutazone, mofezolac, morazone, morphine, morphine hydrochloride, morphine sulfate, morpholine salicylate, myrophine, nabumetone, nalbuphine, 1-naphthyl salicylate, naproxen, narceine, nefopam, nicomorphine, nifenazone, niflumic acid, nimesulide, 5'-nitro-2'-propoxyacetanilide, norlevorphanol, normethadone, normorphine, norpipanone, olsalazine, opium, oxaceprol, oxametacine, oxaprozin, oxycodone, oxymorphone, oxyphenbutazone, papaveretum, paranyline, parsalimide, pentazocine, perisoxal, phenacetin, phenadoxone, phenazocine, phenazopyridine hydrochloride, phenocoll, phenoperidine, phenopyrazone, phenyl acetylsalicylate, phenylbutazone, phenyl salicylate, phenylramidol, piketoprofen, piminodine, pipebuzone, piperylone, piprofen, pirazolac, piritramide, piroxicam, pranoprofen, proglumetacin, proheptazine, promedol, propacetamol, propiram, propoxyphene, propyphenazone, proquazone, protizinic acid, ramifenazone, remifentanyl, rimazolium metilsulfate, salacetamide, salicin, salicylamide, salicylamide o-acetic acid, salicylsulfuric acid, salsalte, salverine, simetride, sodium salicylate, sufentanil, sulfasalazine, sulindac, superoxide dismutase, suprofen, suxibuzone, talniflumate, tenidap, tenoxicam, terofenamate, tetrandrine, thiazolinobutazone, tiaprofenic acid, tiaramide, tilidine, tinoridine, tolfenamic acid, tolmetin, tramadol, tropesin, viminol, xenbucin, ximoprofen, zaltoprofen, and zomepirac.

41. (Withdrawn) The composition of claim 38, in which the vasomodulator is selected from the group consisting of caffeine, theobromine, and theophylline.

42. (Withdrawn) The composition of claim 38, in which the NSAID is selected from the group consisting of nabumetone, tiaramide, proquazone, bufexamac, flumizole, epirazole, tinoridine, timegadine, dapsone, aspirin, diflunisal, benorylate, fosfosal, diclofenac, alclofenac,

fenclofenac, etodolac, indomethacin, sulindac, tolmetin, fentiazac, tilomisolet, carprofen, fenbuten, flurbiprofen, ketoprofen, oxaprozin, suprofen, tiaprofenic acid, ibuprofen, naproxen, fenoprofen, indoprofen, pirofen, flufenamic, mefenamic, meclofenamic, niflumic, oxyphenbutazone, phenylbutazone, apazone, feprazone, piroxicam, sudoxicam, isoxicam, and tenoxicam.

43. (Withdrawn) The composition of claim 38, in which the COX-2 inhibitor is selected from the group consisting of celecoxib, rofecoxib, meloxicam, valdecoxib, parecoxib, etoricoxib, SC-236, NS-398, SC-58125, SC-57666, SC-558, SC-560, etodolac, DFU, monteleukast, L-745337, L-761066, L-761000, L-748780, DUP-697, PGV 20229, igiturimod, BF 389, CL 1004, PD 136005, PD 142893, PD 138387, PD 145065, flurbiprofen, nabumetone, flosulide, piroxicam, diclofenac, lumiracoxib, D 1367, R 807, JTE-522, FK-3311, FK 867, FR 140423, FR 115068, GR 253035, RWJ 63556, RWJ 20485, ZK 38997, S 2474, zomepirac analogs, RS 104894, SC 41930, pranlukast, SB 209670, and APHS

44. (Original) The composition of claim 1, which has been sterile filtered.

45. (Withdrawn) A method of making a nimesulide composition comprising contacting particles of nimesulide or a salt thereof with at least one surface stabilizer for a time and under conditions sufficient to provide a nimesulide composition having an effective average particle size of less than 2000 nm, wherein the at least one surface stabilizer is adsorbed on the surface of the nimesulide particles.

46. (Withdrawn) The method of claim 45, wherein said contacting comprises grinding.

47. (Withdrawn) The method of claim 46, wherein said grinding comprises wet grinding.

48. (Withdrawn) The method of claim 45, wherein said contacting comprises homogenizing.

49. (Withdrawn) The method of claim 45, wherein said contacting comprises:

- (a) dissolving the particles of nimesulide or a salt thereof in a solvent;
- (b) adding the resulting nimesulide solution to a solution comprising at least one surface stabilizer; and
- (c) precipitating the solubilized nimesulide having at least one surface stabilizer adsorbed on the surface thereof by the addition thereto of a non-solvent.

50. (Withdrawn) The method of claim 45, wherein the nimesulide or a salt thereof is selected from the group consisting of a crystalline phase, an amorphous phase, and a semi-crystalline phase.

51. (Withdrawn) The method of claim 45, wherein the effective average particle size of the nimesulide particles is selected from the group consisting of less than 1900 nm, less than 1800 nm, less than 1700 nm, less than 1600 nm, less than 1500 nm, less than 1000 nm, less than 1400 nm, less than 1300 nm, less than 1200 nm, less than 1100 nm, less than 900 nm, less than 800 nm, less than 700 nm, less than 600 nm, less than 500 nm, less than 400 nm, less than 300 nm, less than 250 nm, less than 200 nm, less than 100 nm, less than 75 nm, and less than 50 nm.

52. (Withdrawn) The method of claim 45, wherein the composition is formulated for administration selected from the group consisting of oral, pulmonary, rectal, ophthalmic, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, local, buccal, nasal, and topical administration.

53. (Withdrawn) The method of claim 45, wherein the composition further comprises one or more pharmaceutically acceptable excipients, carriers, or a combination thereof.

54. (Withdrawn) The method of claim 45, wherein the nimesulide or a salt thereof is present in an amount selected from the group consisting of from about 99.5% to about 0.001%, from about 95% to about 0.1%, and from about 90% to about 0.5%, by weight, based on the total combined dry weight of the nimesulide or a salt thereof and at least one surface stabilizer, not including other excipients.

55. (Withdrawn) The method of claim 45, wherein the at least one surface stabilizer is present in an amount selected from the group consisting of from about 0.5% to about 99.999%, from about 5.0% to about 99.9%, and from about 10% to about 99.5% by weight, based on the total combined dry weight of the nimesulide or a salt thereof and at least one surface stabilizer, not including other excipients.

56. (Withdrawn) The method of claim 45, comprising at two surface stabilizers.

57. (Withdrawn) The method of claim 45, wherein the surface stabilizer is selected from the group consisting of an anionic surface stabilizer, a cationic surface stabilizer, a zwitterionic surface stabilizer, a non-ionic surface stabilizer, and an ionic surface stabilizer.

58. (Withdrawn) The method of claim 57, wherein the at least one surface stabilizer is selected from the group consisting of cetyl pyridinium chloride, gelatin, casein, phosphatides, dextran, glycerol, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, dodecyl trimethyl ammonium bromide, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, hydroxypropyl celluloses, hypromellose, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hypromellose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and

formaldehyde, poloxamers; poloxamines, a charged phospholipid, dioctylsulfosuccinate, dialkylesters of sodium sulfosuccinic acid, sodium lauryl sulfate, alkyl aryl polyether sulfonates, mixtures of sucrose stearate and sucrose distearate, p-isononylphenoxypoly-(glycidol), decanoyl-N-methylglucamide; n-decyl β -D-glucopyranoside; n-decyl β -D-maltopyranoside; n-dodecyl β -D-glucopyranoside; n-dodecyl β -D-maltoside; heptanoyl-N-methylglucamide; n-heptyl- β -D-glucopyranoside; n-heptyl β -D-thiogluconoside; n-hexyl β -D-glucopyranoside; nonanoyl-N-methylglucamide; n-nonyl β -D-glucopyranoside; octanoyl-N-methylglucamide; n-octyl- β -D-glucopyranoside; octyl β -D-thiogluconopyranoside; lysozyme, PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, and random copolymers of vinyl acetate and vinyl pyrrolidone.

59. (Withdrawn) The method of claim 57, wherein the at least one cationic surface stabilizer is selected from the group consisting of a polymer, a biopolymer, a polysaccharide, a cellulosic, an alginate, a nonpolymeric compound, and a phospholipid.

60. (Withdrawn) The method of claim 57, wherein the surface stabilizer is selected from the group consisting of cationic lipids, polymethylmethacrylate trimethylammonium bromide, sulfonium compounds, polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate, hexadecyltrimethyl ammonium bromide, phosphonium compounds, quarternary ammonium compounds, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride, coconut trimethyl ammonium bromide, coconut methyl dihydroxyethyl ammonium chloride, coconut methyl dihydroxyethyl ammonium bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride bromide, C₁₂₋₁₅dimethyl hydroxyethyl ammonium chloride, C₁₂₋₁₅dimethyl hydroxyethyl ammonium chloride bromide, coconut dimethyl hydroxyethyl ammonium chloride, coconut dimethyl hydroxyethyl ammonium bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride, lauryl dimethyl benzyl ammonium bromide, lauryl dimethyl (ethenoxy)₄ ammonium chloride, lauryl dimethyl

(ethenoxy)₄ ammonium bromide, N-alkyl (C₁₂₋₁₈)dimethylbenzyl ammonium chloride, N-alkyl (C₁₄₋₁₈)dimethyl-benzyl ammonium chloride, N-tetradecyldimethylbenzyl ammonium chloride monohydrate, dimethyl didecyl ammonium chloride, N-alkyl and (C₁₂₋₁₄) dimethyl 1-naphthylmethyl ammonium chloride, trimethylammonium halide, alkyl-trimethylammonium salts, dialkyl-dimethylammonium salts, lauryl trimethyl ammonium chloride, ethoxylated alkyamidoalkyldialkylammonium salt, an ethoxylated trialkyl ammonium salt, dialkylbenzene dialkylammonium chloride, N-didecyldimethyl ammonium chloride, N-tetradecyldimethylbenzyl ammonium, chloride monohydrate, N-alkyl(C₁₂₋₁₄) dimethyl 1-naphthylmethyl ammonium chloride, dodecyldimethylbenzyl ammonium chloride, dialkyl benzenealkyl ammonium chloride, lauryl trimethyl ammonium chloride, alkylbenzyl methyl ammonium chloride, alkyl benzyl dimethyl ammonium bromide, C₁₂ trimethyl ammonium bromides, C₁₅ trimethyl ammonium bromides, C₁₇ trimethyl ammonium bromides, dodecylbenzyl triethyl ammonium chloride, polydiallyldimethylammonium chloride (DADMAC), dimethyl ammonium chlorides, alkyltrimethylammonium halogenides, tricetyl methyl ammonium chloride, decyltrimethylammonium bromide, dodecyltriethylammonium bromide, tetradecyltrimethylammonium bromide, methyl trioctylammonium chloride, polyquaternium 10, tetrabutylammonium bromide, benzyl trimethylammonium bromide, choline esters, benzalkonium chloride, stearylalkonium chloride compounds, cetyl pyridinium bromide, cetyl pyridinium chloride, halide salts of quaternized polyoxyethylalkylamines, quaternized ammonium salt polymers, alkyl pyridinium salts; amines, amine salts, amine oxides, imide azolinium salts, protonated quaternary acrylamides, methylated quaternary polymers, and cationic guar.

61. (Withdrawn) The method of claim 45, utilizing as a surface stabilizer a random copolymer of vinyl acetate and vinyl pyrrolidone, hydroxypropylmethyl cellulose, or tyloxapol.

62. (Withdrawn) The method of any of claims 57, 59, or 60, wherein the composition is bioadhesive.

63. (Withdrawn) A method of treating a subject in need comprising administering to the subject an effective amount of a composition comprising:

- (a) particles of nimesulide or a salt thereof, wherein the nimesulide particles have an effective average particle size of less than 2000 nm; and
- (b) at least one surface stabilizer adsorbed on the surface of the nimesulide particles.

64. (Withdrawn) The method of claim 63, wherein the nimesulide or a salt thereof is selected from the group consisting of a crystalline phase, an amorphous phase, and a semi-crystalline phase.

65. (Withdrawn) The method of claim 63, wherein the effective average particle size of the nimesulide particles is selected from the group consisting of less than 1900 nm, less than 1800 nm, less than 1700 nm, less than 1600 nm, less than 1500 nm, less than 1400 nm, less than 1300 nm, less than 1200 nm, less than 1100 nm, less than 1000 nm, less than 900 nm, less than 800 nm, less than 700 nm, less than 600 nm, less than 500 nm, less than 400 nm, less than 300 nm, less than 250 nm, less than 200 nm, less than 100 nm, less than 75 nm, and less than 50 nm.

66. (Withdrawn) The method of claim 63, wherein the composition is formulated for administration selected from the group consisting of oral, pulmonary, rectal, ophthalmic, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, local, buccal, nasal, and topical administration.

67. (Withdrawn) The method of claim 63, wherein the composition is a dosage form selected from the group consisting of liquid dispersions, oral suspensions, gels, aerosols, ointments, creams, controlled release formulations, fast melt formulations, lyophilized formulations, tablets, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations.

68. (Withdrawn) The method of claim 63, wherein the composition further comprises one or more pharmaceutically acceptable excipients, carriers, or a combination thereof.

69. (Withdrawn) The method of claim 63, wherein the nimesulide or a salt thereof is present in an amount selected from the group consisting of from about 99.5% to about 0.001%, from about 95% to about 0.1%, and from about 90% to about 0.5%, by weight, based on the total combined dry weight of the nimesulide or a salt thereof and at least one surface stabilizer, not including other excipients.

70. (Withdrawn) The method of claim 63, wherein the at least one surface stabilizer is present in an amount selected from the group consisting of from about 0.5% to about 99.999% by weight, from about 5.0% to about 99.9% by weight, and from about 10% to about 99.5% by weight, based on the total combined dry weight of the nimesulide or a salt thereof and at least one surface stabilizer, not including other excipients.

71. (Withdrawn) The method of claim 63, comprising at two surface stabilizers.

72. (Withdrawn) The method of claim 63, wherein the surface stabilizer is selected from the group consisting of an anionic surface stabilizer, a cationic surface stabilizer, a zwitterionic surface stabilizer, a non-ionic surface stabilizer, and an ionic surface stabilizer.

73. (Withdrawn) The method of claim 72, wherein the at least one surface stabilizer is selected from the group consisting of cetyl pyridinium chloride, gelatin, casein, phosphatides, dextran, glycerol, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, dodecyl trimethyl ammonium bromide, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, hydroxypropyl celluloses, hypromellose, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hypromellose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and

formaldehyde, poloxamers; poloxamines, a charged phospholipid, dioctylsulfosuccinate, dialkylesters of sodium sulfosuccinic acid, sodium lauryl sulfate, alkyl aryl polyether sulfonates, mixtures of sucrose stearate and sucrose distearate, p-isononylphenoxypoly-(glycidol), decanoyl-N-methylglucamide; n-decyl β -D-glucopyranoside; n-decyl β -D-maltopyranoside; n-dodecyl β -D-glucopyranoside; n-dodecyl β -D-maltoside; heptanoyl-N-methylglucamide; n-heptyl- β -D-glucopyranoside; n-heptyl β -D-thioglucoside; n-hexyl β -D-glucopyranoside; nonanoyl-N-methylglucamide; n-nonyl β -D-glucopyranoside; octanoyl-N-methylglucamide; n-octyl- β -D-glucopyranoside; octyl β -D-thioglucopyranoside; lysozyme, PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, and random copolymers of vinyl acetate and vinyl pyrrolidone.

74. (Withdrawn) The method of claim 72, wherein the at least one cationic surface stabilizer is selected from the group consisting of a polymer, a biopolymer, a polysaccharide, a cellulosic, an alginate, a nonpolymeric compound, and a phospholipid.

75. (Withdrawn) The method of claim 72, wherein the surface stabilizer is selected from the group consisting of benzalkonium chloride, polymethylmethacrylate trimethylammonium bromide, polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate, hexadecyltrimethyl ammonium bromide, cationic lipids, sulfonium compounds, phosphonium compounds, quarternary ammonium compounds, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride, coconut trimethyl ammonium bromide, coconut methyl dihydroxyethyl ammonium chloride, coconut methyl dihydroxyethyl ammonium bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride bromide, C₁₂₋₁₅dimethyl hydroxyethyl ammonium chloride, C₁₂₋₁₅dimethyl hydroxyethyl ammonium chloride bromide, coconut dimethyl hydroxyethyl ammonium chloride, coconut dimethyl hydroxyethyl ammonium bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride, lauryl dimethyl benzyl ammonium bromide, lauryl

dimethyl (ethenoxy)₄ ammonium chloride, lauryl dimethyl (ethenoxy)₄ ammonium bromide, N-alkyl (C₁₂₋₁₈)dimethylbenzyl ammonium chloride, N-alkyl (C₁₄₋₁₈)dimethyl-benzyl ammonium chloride, N-tetradecyldimethylbenzyl ammonium chloride monohydrate, dimethyl didecyl ammonium chloride, N-alkyl and (C₁₂₋₁₄) dimethyl 1-naphthylmethyl ammonium chloride, trimethylammonium halide, alkyl-trimethylammonium salts, dialkyl-dimethylammonium salts, lauryl trimethyl ammonium chloride, ethoxylated alkyamidoalkyldialkylammonium salt, an ethoxylated trialkyl ammonium salt, dialkylbenzene dialkylammonium chloride, N-didecyl dimethyl ammonium chloride, N-tetradecyldimethylbenzyl ammonium, chloride monohydrate, N-alkyl(C₁₂₋₁₄) dimethyl 1-naphthylmethyl ammonium chloride, dodecyl dimethylbenzyl ammonium chloride, dialkyl benzenealkyl ammonium chloride, lauryl trimethyl ammonium chloride, alkylbenzyl methyl ammonium chloride, alkyl benzyl dimethyl ammonium bromide, C₁₂ trimethyl ammonium bromides, C₁₅ trimethyl ammonium bromides, C₁₇ trimethyl ammonium bromides, dodecylbenzyl triethyl ammonium chloride, polydiallyldimethylammonium chloride (DADMAC), dimethyl ammonium chlorides, alkyl dimethylammonium halogenides, tricetyl methyl ammonium chloride, decyltrimethylammonium bromide, dodecyltriethylammonium bromide, tetradecyltrimethylammonium bromide, methyl trioctylammonium chloride, polyquaternium 10, tetrabutylammonium bromide, benzyl trimethylammonium bromide, choline esters, benzalkonium chloride, stearylalkonium chloride compounds, cetyl pyridinium bromide, cetyl pyridinium chloride, halide salts of quaternized polyoxyethylalkylamines, quaternized ammonium salt polymers, alkyl pyridinium salts; amines, amine salts, amine oxides, imide azolinium salts, protonated quaternary acrylamides, methylated quaternary polymers, and cationic guar.

76. (Withdrawn) The method of claim 63, utilizing as a surface stabilizer a random copolymer of vinyl acetate and vinyl pyrrolidone, hydroxypropylmethyl cellulose, or tyloxapol.

77. (Withdrawn) The method of any of claims 72, 74, or 75, wherein the composition is bioadhesive.

78. (Withdrawn) The method of claim 63, wherein administration of the nimesulide composition does not produce a difference in the absorption levels of the nimesulide composition when administered to a patient under fed as compared to fasting conditions, when administered to a human.

79. (Withdrawn) The method of claim 78, wherein the difference in absorption of the nimesulide composition of the invention, when administered in the fed versus the fasted state, is selected from the group consisting of less than 100%, less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, and less than 3%.

80. (Withdrawn) The method of claim 63, wherein administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state, when administered to a human.

81. (Withdrawn) The method of claim 80, wherein "bioequivalency" is established by a 90% Confidence Interval of between 0.80 and 1.25 for both C_{max} and AUC, when administered to a human.

82. (Withdrawn) The method of claim 80, wherein "bioequivalency" is established by a 90% Confidence Interval of between 0.80 and 1.25 for AUC and a 90% Confidence Interval of between 0.70 to 1.43 for C_{max} , when administered to a human.

83. (Withdrawn) The method of claim 63, wherein the T_{max} of the nimesulide, when assayed in the plasma of a mammalian subject following administration, is less than the T_{max} for a conventional, non-nanoparticulate form of nimesulide, administered at the same dosage.

84. (Withdrawn) The method of claim 83, wherein the T_{\max} is selected from the group consisting of not greater than 90%, not greater than 80%, not greater than 70%, not greater than 60%, not greater than 50%, not greater than 30%, not greater than 25%, not greater than 20%, not greater than 15%, and not greater than 10% of the T_{\max} , exhibited by a non-nanoparticulate formulation of nimesulide, administered at the same dosage.

85. (Withdrawn) The method of claim 63, wherein the C_{\max} of the nimesulide, when assayed in the plasma of a mammalian subject following administration, is greater than the C_{\max} for a conventional, non-nanoparticulate form of nimesulide, administered at the same dosage.

86. (Withdrawn) The method of claim 85, wherein the C_{\max} is selected from the group consisting of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, and at least 100% greater than the C_{\max} exhibited by a non-nanoparticulate formulation of nimesulide, administered at the same dosage.

87. (Withdrawn) The method of claim 63, wherein the AUC of the nimesulide, when assayed in the plasma of a mammalian subject following administration, is greater than the AUC for a conventional, non-nanoparticulate form of nimesulide, administered at the same dosage.

88. (Withdrawn) The method of claim 87, wherein the AUC is selected from the group consisting of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, and at least 100% greater than the AUC exhibited by a non-nanoparticulate formulation of nimesulide, administered at the same dosage.

89. (Withdrawn) The method of claim 63, additionally comprising administering one or more non-nimesulide active agents.

90. (Withdrawn) The method of claim 63, additionally comprising administering one or more non-nimesulide active agents effective for treating fever, inflammation or pain.

91. (Withdrawn) The method of claim 89, wherein said non-nimesulide active agent is selected from the group consisting of an analgesic, an anti-inflammatory, an antipyretic, and a vasomodulator.

92. (Withdrawn) The method of claim 89, wherein said non-nimesulide active agent is selected from the group consisting of nutraceuticals, proteins, peptides, nucleotides, amino acids, anti-obesity drugs, central nervous system stimulants, carotenoids, corticosteroids, elastase inhibitors, anti-fungals, oncology therapies, anti-emetics, analgesics, cardiovascular agents, anti-inflammatory agents, NSAIDs, non-nimesulide COX-2 inhibitors, anthelmintics, anti-arrhythmic agents, antibiotics, anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytics, sedatives, astringents, alpha-adrenergic receptor blocking agents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiac inotropic agents, contrast media, corticosteroids, cough suppressants, diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics, haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones, anti-allergic agents, stimulants and anoretics, sympathomimetics, thyroid agents, vasodilators, vasomodulators, and xanthines.

93. (Withdrawn) The method of claim 63, wherein the subject is a human.

94. (Withdrawn) The method of claim 63, wherein the method is used to treat a condition selected from the group consisting of rheumatic and joint diseases, arthritis, rheumatoid arthritis, osteoarthritis, peri-arthritis, tendonitis, bursitis, ankylosing spondylitis, joint stiffness, lower back pain, gynecological conditions, menstrual migraine attack, dysmenorrhoea, pelvic inflammatory disease, urological conditions, urethritis, prostatitis, and vesiculitis pyrexia, cardiovascular diseases, atherosclerosis, hypotension, thrombophlebitis, arthrosis; inflammatory conditions, otitis, rhinitis, sinusitis, pharyngitis, bronchitis nephrotoxicity, mastitis, asthma,

cancer, trauma, surgery, migraine headaches, kidney disease, Alzheimer's disease, familial adenomatous polyposis, diarrhea, colonic adenomas bone resorption, and related conditions.

95. (Withdrawn) The method of claim 63, wherein the method is used to treat a condition where anti-inflammatory agents, anti-angiogenesis agents, antitumorigenic agents, immunosuppressive agents, NSAIDs, COX-2 inhibitors, analgesic agents, anti-thrombotic agents, narcotics, or antifebrile agents are typically used.

REMARKS

Applicants respectfully request consideration of the following comments upon continued examination of the present application.

I. Status of the Claims

No claim amendment is made in this response. Claims 1-95 are pending with claims 32-35, 39, 41-43 and 45-95 withdrawn from consideration. Upon allowance of the product claims, Applicants respectfully request rejoinder of the corresponding method claims.

II. Rejection of Claims under 35 U.S.C. §103(a)

A. Reiner and Ryde

Claims 1-15 and 27-31 remain rejected under 35 U.S.C. §103(a) for allegedly being obvious over U.S. Patent No. 5,711,961 to Reiner et al. ("Reiner") in view of U.S. Patent No. 6,375,986 to Ryde et al. ("Ryde"). Applicants respectfully traverse the rejection.

With a correct read of the references, the combined teachings of the cited art fail to render the claimed invention obvious.

(1) The Examiner incorrectly interprets the claim limitation "effective average particle size"

The Examiner incorrectly equates a teaching in Reiner with the following claim element: effective average particle size of less than 2000 nm.

First, Reiner fails to teach the claimed particle size. Reiner merely states in passing that drug particles can occur in the micron range. According to the Examiner, the teaching of Reiner that the drug particles are "in the micron size range" is equivalent to the particle size distribution element required by the claimed invention. This is technically incorrect. Reiner merely mentions its drug particle size in passing, at column 4, lines 64-65: "A syrup, possibly suitably

flavored, containing the micronized drug in suspension. . . .” This bare teaching is insufficient to enable one of ordinary skill in the art about an effective average particle size as defined in the instant claims.

For example, by definition, “micron size range” typically encompasses the particle size between 1 micron and 999 microns. In contrast, the instant claim requires an *effective average particle size* of less than 2000 nm. As explicitly defined in the specification, “an effective average particle size of less than 2000 nm” means that at least 50% of the nimesulide particles have a particle size less than 2000 nm. *See* page 19, paragraph [0066]. As such, “an effective average particle size of less than about 2000 nm” is represented by a bell-shaped curve with a peak of particle size around 2000 nm. Accordingly, the brief mentioning of drug particle size in the micron size range of between 1 and 999 microns (i.e., Reiner) fails to teach or suggest the particle size distribution of the claimed invention. Therefore, Reiner fails to teach this limitation of the claims.

The following question logically follows: If Reiner does not meet the claimed limitation and Ryde does, why would one skilled in the art modify the micron-sized drug particles in Reiner so that they have a size distribution where 50 % of the particles are smaller than 2000 nm and 50% are larger than 2000 nm as taught by Ryde? The rejection fails to provide a valid answer to this question for at least the following reasons.

(2) The reason to combine Reiner and Ryde is lacking.

The Examiner asserts that “the only aspect of the claimed invention not disclosed by Reiner et al.” is “stabilizing agents adsorbed onto the surface of the micron-sized nimesulide particles” (final Office Action, page 7, lines 14-18). The Examiner contends that Ryde compensates for the acknowledged deficiencies of Reiner.

- (i) **A lack of evidence that the combination of reference cannot be made does not support the conclusion that the combination of references is obvious.**

The Examiner's rationale for combining the references is that one skilled in the art would not expect the advantage of Ryde to diminish the advantage of Reiner. Such a rationale is not based on fact. A lack of evidence teaching away from combining the references as suggested by the Examiner is not evidence of the obviousness of the invention in view of the references. This new test created by the Examiner is clearly not based upon any patent law premise. Indeed, this is an indication that the rejection rationale is based on nothing but impermissible hindsight as articulated below.

- (ii) **Reiner and Ryde are directed to unrelated technologies.**

Both of the cited references are directed to solving vastly different problems identified in the relevant prior art, and there is no suggestion or teaching in either reference that the disclosed technology could be applicable to the claimed invention. Because Reiner and Ryde are directed to unrelated technologies and advantages, it is only with the aide of impermissible hindsight gleaned from the instant claims that the Examiner was able to combine these references.

For example, Reiner addresses the problem present in the prior art regarding unpalatability of a dosage form by utilizing a lacquer-coated chewing gum tablet, which achieves a balance of plasmatic and haematic absorption of the drug present in the dosage form. See column 5, lines 54-60. Reiner does not expressly or impliedly teach that the described micronized drug particles are unstable in any way, which could have prompted a solution by requiring a surface stabilizer adsorbed on the surface of the micronized drug particles. Nor does Reiner suggest that the micron sized drug particles do not dissolve adequately, thus requiring the need for further size reduction to increase the dissolution of the drug particles.

It is well known that ultra fine particles are unstable due to their surface charge and properties, etc. and they tend to agglomerate and aggregate to form larger particles to regain stability. Utilizing steric surface stabilizers is one way to solve the stability problem because surface stabilizers can adsorb on the surface of the nanoparticulate drug particles, thereby preventing agglomeration or aggregation. Ryde, on the other hand, addresses the problem present in the prior art regarding redispersibility of solid dose particulate compositions by discovering a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate (DOSS), which results in a superior redispersibility profile of the solid dose composition. See abstract, and column 5, lines 60-66.

One skilled in the art would not have any reason to combine these references because the lacquer coating (Reiner) and the synergistic combination of surface stabilizers (Ryde), or the unpalatability (Reiner) and redispersibility (Ryde), have no correlation to each other. Thus, only with the use of impermissible hindsight is the Examiner able to select these two vastly different prior art references and selects specific excerpts from them to construct the claimed invention. A rationale to combine references cannot be based upon hindsight alone and there is no other articulated reason espoused by the Examiner explaining why one skilled in the art would combine the teachings of Reiner and Ryde. Accordingly, the rejection is in error.

(iii) The Examiner misinterprets Applicants' characterization of the claimed invention

In an attempt to bridge the gap between the prior art and the claimed invention (i.e., to justify a rejection that lacks a reason to combine the cited references), the Examiner erroneously states that "the claimed composition as depicted in (A) is simply a "zoomed-in" view of the micronized drug layer of (B) as disclosed by Reiner et al., minus the surface stabilizer adsorbed onto the surface of the micronized drug particles" (final Office Action, page 7, lines 1-3).

This interpretation of the claimed invention errs in at least two aspects: (a) the Examiner takes the drug layer of Reiner's composition out of context and puts it in a "vacuum" to fit in the

claim elements; and (b) the Examiner attempts to fill in the information missing from the prior art based on the knowledge or the claimed invention, again, with the aid of impermissible hindsight.

Concerning point (a), the MPEP urges that the Examiner should consider the prior art as a whole rather than isolating an element from prior art and comparing it with the claimed invention. MPEP 2141.02 (“Ascertaining the differences between the prior art and the claims at issue requires interpreting the claim language, and considering both the invention and the prior art references as a whole.”)

Turning to point (b), the Examiner would not have had “zoomed in” the drug layer of Reiner’s composition in the absence of any knowledge from the claimed invention. This is because, as discussed below, one skilled in the art would not have any reason to modify Reiner’s composition in view of Ryde’s teaching.

Accordingly, the Examiner has failed to meet the initial burden to establish a *prima facie* case of obviousness.

(3) The modification of Reiner in view of Ryde would destroy the intended purpose of a component in Reiner

For arguments’ sake, Applicants assert that even if the Examiner presented a valid reason based in fact to modify Reiner in view of Ryde, such a modified Reiner would destroy the intended purpose of certain components of Reiner.

In order to teach the claimed limitation of a surface stabilizer on the drug particles, the Examiner appears to suggest that one skilled in the art when combining the teachings of Reiner and Ryde would remove the lacquer layer of Reiner’s composition, which contains celluloses and polyethylene glycols, and make these celluloses and polyethylene glycols the surface stabilizers which would then be adsorbed on the surface of the drug particles. This logic is contrary to MPEP 2143.01, “[i]f [a] proposed modification would render the prior art invention being

modified unsatisfactory for its intended purpose, then there is no suggestion or motivation to make the proposed modification. *In re Gordon*, 733 F.2d 900, 221 USPQ 1125 (Fed. Cir. 1984)” In the present case, the change of the lacquer coating into surface stabilizers would require removal of the lacquer coating to obtain the claimed invention, which is a deviation from the intended purpose of Reiner’s composition.

Alternatively, if the Examiner suggests adding a surface stabilizer to Reiner’s composition in view of Ryde’s teaching, this modification would result in a lacquer-coated gum tablet having surface stabilizers adsorbed to the surface of drug particles which are in the micron-size range. There is no teaching in either of the cited references that micron-sized drug particles need surface stabilizers to prevent aggregation. There is simply no basis in the cited references for the Examiner to reach this conclusion.

B. Reiner, Ryde and Tertiary References

Claims 1, 10-13 and 15-26 remain rejected under 35 U.S.C. §103(a) for allegedly being obvious over Reiner and Ryde in view of U.S. Patent No. 5,552,160 to Liversidge *et al.* (“Liversidge”). Claims 1 and 16-26 remain rejected under 35 U.S.C. §103(a) for allegedly being obvious over Reiner and Ryde in view of Singh *et al.*, *Analytical Profiles of Drug Substances and Excipients*, 28: 197-249 (2001) (“Singh”) and U.S. Patent No. 5,510,118 to Bosch *et al.* (“Bosch”). Claims 1, 36-38 and 40 remain rejected under 35 U.S.C. §103(a) for allegedly being obvious over Reiner and Ryde in view of Singh and the Merck Index, 12th ed., Merck & Co., Codeine, pp. 416-417 (1996). Finally, claims 1 and 44 remain rejected under 35 U.S.C. §103(a) for allegedly being obvious over Reiner and Ryde in view of U.S. Patent No. 5,776,563 to Buhl *et al.* (“Buhl”). Applicants respectfully traverse all of these rejections.

The teachings of Reiner and Ryde are discussed *supra*. Liversidge, Singh, and Bosch are cited for the alleged teaching of T_{max}, C_{max} or AUC profile of nimesulide. The Merck Index is cited for the alleged teaching that codeine has analgesic properties. Finally, Buhl is cited for the

alleged teaching of sterile filtration. Because none of the tertiary references remedy the deficiencies of Reiner and Ryde as discussed above, withdrawal of the rejections is respectfully requested.

CONCLUSION

The present application is now in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested. The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment instructions in EFS-Web being incorrect or absent, resulting in a rejected or incorrect credit card transaction, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicants hereby petition for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Respectfully submitted,

Date: Nov 5, 2019

By Michele M. Simkin

FOLEY & LARDNER LLP
Customer Number: 31049
Telephone: (202) 672-5538
Facsimile: (202) 672-5399

Michele M. Simkin
Attorney for Applicant
Registration No. 34,717